Aptose signs $7M investment agreement with Hanmi Pharmaceutical; first $3M tranche closed

Aptose Biosciences Inc.

First tranche of $3.0M closed at $4.448/share (premium to $4.04 minimum price) for 668,449 shares.
Second tranche of $4.0M contingent on milestones: CofA, Lonza change orders, positive tuspetinib data by June 30, 2024.
Investor Rights Agreement: Hanmi gets nomination right (≥10% ownership) and participation right in future offerings.
Hanmi currently owns ~12.07% of APTO; second tranche capped at 19.99% blocker.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aptose Biosciences Inc. entered into Subscription Agreement with Hanmi Pharmaceutical Co., Ltd. valued at up to $7,000,000 (effective 2023-09-06).

Action: entry
Agreement: equity purchase
Counterparty: Hanmi Pharmaceutical Co., Ltd.
Value: up to $7,000,000
Effective: 2023-09-06

Exact text from the filing

On September 6, 2023, Aptose Biosciences Inc., a Canadian corporation (the “ Corporation ”), entered into a subscription agreement (the “ Subscription Agreement ”) with Hanmi Pharmaceutical Co., Ltd., a corporation formed under the laws of the Republic of Korea (the “ Hanmi Pharmaceutical ”), pursuant to which the Corporation agreed to sell and issue to Hanmi Pharmaceutical and Hanmi Pharmaceutical agreed to purchase from the Corporation up to $7.0 million of the Corporation’s common shares

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aptose Biosciences Inc. entered into Investor Rights Agreement with Hanmi Pharmaceutical Co., Ltd. (effective 2023-09-06).

Action: entry
Agreement: equity purchase
Counterparty: Hanmi Pharmaceutical Co., Ltd.
Effective: 2023-09-06

Exact text from the filing

In connection with the Hanmi Investment, the Corporation and Hanmi Pharmaceutical entered into an Investor Rights Agreement (the “ Investor Rights Agreement ”).

View on SEC.gov

273 material agreements filed in the last 30 days. Browse all material agreements →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-005679

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.